- Sponsored Content
- Downstream Processing
Security of Supply Risk Mitigation in HCP Monitoring
January 18, 2022
2 Min Read
The most common method scientists use to monitor host cell protein (HCP) levels in biologics is the enzyme-linked immunosorbent assay (ELISA). For the reagent, security of supply is a regulatory requirement — it’s a factor that’s critical to consistently monitoring HCP during biologic production. In this webinar, we discuss why security of supply is important, the consequences of not having it, and how to mitigate this risk.
Why security of supply is critical to your HCP plans
Consequences of not securing supply upfront
How to mitigate risk by securing supply distribution
Differences between antisera batch and ELISA lot
Joe Hirano, PhD is Imaging and Western Blotting program manager at Cytiva based in Uppsala, Sweden, where he manages products and their applications between Research and Development, and external collaborators to support customers. Since joining the company in 2000, Joe has been working with genomics, protein research, and biomanufacturing products, including electrophoresis, Western blot, imaging, and upstream and downstream bioprocess products. His current focus is on the analysis of host cell proteins and other impurities. Before joining the biopharma industry, Joe studied marine biology as a research scientist.
David Chimento, PhD, is vice president of the custom services division at Rockland Immunochemicals, based in Limerick, Pennsylvania, US. David coordinates and oversees Research and Development engagements for both internal and external stakeholders with a focus on project design and strategy for customers. David joined Rockland Immunochemicals in 2008 and has been working on critical reagent development and assay development. He has a strong interest in creating tools for traditional and emerging biotherapeutics and biomanufacturing. One of his current focus areas is on bioprocessing and the analysis of host cell proteins and other impurities. Before joining the biotechnology industry, David studied microbiology and molecular biophysics with a focus on protein structure and protein-protein interactions.
Click here to register for this webinar.
Andelyn to make viral vectors in FDA-NIH led gene therapy consortiumMar 1, 2024|1 Min Read
GLP-1 drug demand drives $250m fill/finish expansion for SimtraMar 1, 2024|3 Min Read
AstraZeneca to build global strategic center in ShanghaiMar 1, 2024|3 Min Read
Ins & Outs: Gonzalez but not forgotten at AbbVieFeb 29, 2024|2 Min Read
Mar 11 - Mar 14, 2024
Mar 11 - Mar 14, 2024
Accelerate speed to market for your next generation mAbs, vaccines, cell therapy, and gene therapy products. At the BioProcess International US West event in San Diego, CA, in March 2024 you can access today's innovative strategies and technologies designed to improve process efficiencies and maintain product quality across all phases of bioprocessing.Agenda